Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Androgen deprivation with or without docetaxel in asymptomatic prostate cancer with rising PSA after local therapy
2007-000323-17Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Apr 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in prostate cancer (PCa) comparing ADT with leuprolide with ADT with leuprolide plus docetaxel (2 arms). Primary endpoint: Progression-free survival. Started Apr 2007; status: terminated.
02
Drugs
docetaxelleuprolide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2007-000323-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000323-17.